Life Technologies Enters into an Exclusive License and Supply Agreement for
Life Technologies' proprietary Dynabeads®CD3/CD28 CTS™ utilized to isolate,
activate and expand therapeutic T cells for oncology indications
CARLSBAD, Calif., July 31, 2013
CARLSBAD, Calif., July 31, 2013 /PRNewswire/ --Life Technologies Corporation
(NASDAQ: LIFE) today announced that the company has signed a long-term supply
and exclusive licensing agreement with Novartis for immunotherapeutics
involving T cells modified to express chimeric antigen receptors for the
treatment of cancer. Life Technologies will provide the company's proprietary
technology, Dynabeads® CD3/CD28 CTS™, which possess unique biological
properties suited to production of active, therapeutically relevant immune
The agreement includes rights to use Life Technologies' intellectual property
to perform the resulting therapy, and is exclusive for use in the field of
chimeric antigen receptors for the treatment of cancer.
"The collaboration with Novartis highlights the distinct capabilities that
Life Technologies can provide in the therapeutic realm," said Greg Lucier,
chairman and chief executive officer of Life Technologies. "Taken with our
previous announcements of companion diagnostic collaborations, the current
agreement demonstrates how Life is uniquely positioned to facilitate drug
development through alliances with pharma."
Chimeric antigen receptor T cell based immunotherapy constitutes a novel,
individualized method of combating cancers. Novartis is working to
commercialize technology developed at the University of Pennsylvania that has
demonstrated startling efficacy in research studies. In two 2011
publications^1,2, University of Pennsylvania researchersdescribed application
of immunotherapy in three patients, all of whom experienced durable complete
or partial remission of their cancers within three to four weeks of treatment.
A 2013 publication in the New England Journal of Medicine described complete
responses with one ongoingin two children with leukemia^3.
The personalized therapy consists of removing blood cells from cancer
patients;isolating and activating T cells; genetically modifying the T cells
thereby programming those cells to recognize and attack cancer cells;
expanding the T cells; and, lastly, introducing those cells back into the
body so the patient's immune system can take over. Under the terms of the
current agreement, Life Technologies' Dynabeads® CD3/CD28 CTS™, will be used
to isolate, activate and expand the T cells.
"Dynabeads ® CD3/CD28 CTS™ have unique properties that are ideal for producing
a robust immunotherapeutic," said Oystein Aamellem, head of Cellular Medicine
at Life Technologies. "Not only do the beads assure that T cells are separated
from any unwanted cells, it also triggers the T cells to reproduce in a
natural and controlled manner, ensuring a therapeutically relevant population
is transferred back into the patient."
"The current agreement with Novartis represents a significant step in the
growth of Life Technologies from a research tools provider to a leading
medical device company," said Lucier. "We're very excited about the
opportunity to work with Novartis to deliver novel therapeutics to fill a
critical need in cancer care."
^1Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia.
Porter, David L., et. al.; N Engl J Med 2011; 365:725-733.
^2T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and
Can Establish Memory in Patients with Advanced Leukemia. Kalos, Michael, et.
al.; Sci Transl Med10 August 2011:Vol. 3,Issue 95,p. 95.
^3Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
Grupp, Stephan A., et al.; N Engl J Med 2013; 368;1509-1518
Dynabeads® CD3/CD28 CTS™ are For Research Use or Manufacturing of Cell, Gene,
or Tissue-Based Products. Caution: Not intended for direct administration into
human or animals or For Investigational Use Only.
About Life Technologies
Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology company
that is committed to providing the most innovative products and services to
leading customers in the fields of scientific research, genetic analysis and
applied sciences. With a presence in more than 180 countries, the company's
portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents
and licenses that span the entire biological spectrum -- scientific
exploration, molecular diagnostics, 21^stcentury forensics, regenerative
medicine and agricultural research. Life Technologies has approximately 10,000
employees and had sales of $3.8 billion in 2012.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life
Technologies' anticipated results that involve risks and uncertainties. Some
of the information contained in this press release, including, but not limited
to, statements as to industry trends and Life Technologies' plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made by Life Technologies with the Securities and Exchange
Commission. Life Technologies undertakes no obligation to update or revise any
such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact:
SOURCE Life Technologies Corporation
Press spacebar to pause and continue. Press esc to stop.